Poster ID - **P0815**

DUCRAY
SCIENCE DERMATOLOGIQUE

INTEREST OF AN ANTI-HAIR LOSS SERUM CONTAINING *SILYBUM MARIANUM*, *LESPEDEZA CAPITATA*, MANGANESE PYRROLIDONE CARBOXYLIC ACID IN THE MANAGEMENT OF ANDROGENETIC ALOPECIA IN MEN: AN INTERNATIONAL REAL-WORLD STUDY

Valèrie Mengeaud[1], Alexia Brocario[1], Eva Mantel[1], Virginie Ribet[1], Bianca Maria Piraccini[2]

1. Medical Direction, Laboratoires Dermatologiques Ducray, Pierre Fabre Dermo-Cosmetics & Personal Care, Lavaur, France

2. Piraccini Medical Center, Bologna, Italy

INTRODUCTION & OBJECTIVES

Non scarring hair disorders result in a decrease in visible hair and can significantly impair psychosocial well being and quality of life. The most common form is androgenic alopecia.

The objective of this real-world study was to evaluate the efficacy and tolerance of an anti-hair loss and anchorage serum containing *Silybum marianum* extract, manganese pyrrolidone carboxylic acid, and *Lespedeza capitata* extract in the management of androgenetic alopecia in men in daily dermatological practice.

MATERIALS & METHODS

International (13 countries), open label, real-world, prospective & multicentric study

Focus on androgenetic alopecia in men

522 subjects

≥18 years old

Assessments at each visit:

✓ **Hair density & volume, Tolerance by dermatologists**

✓ **Hair density, volume, strength & thickness by subjects**

T0 — **T3 months** ± 3 weeks


*3 months of **daily-use** of the anti-hair loss serum (Anaphase Neoptide serum) on the scalp **in monotherapy** or **in association with treatments***

RESULTS


Prescription scheme of the anti-hair loss serum



Main associated treatments




Hair aspects assessed by dermatologists



After **3 MONTHS**

Tolerance rated as 'good' to 'very good' by dermatologists for 94.4% of subjects

Hair aspects assessed by subjects



CONCLUSIONS

In **real-life** conditions, daily use of this anti-hair loss serum demonstrated **clinically relevant efficacy** and **very good tolerance** used as monotherapy and in combination with treatments in **men with androgenic alopecia**.

After **3 MONTHS**

HAIR DENSITY

Monotherapy	In combination with treatments
+32%**	+39%**

HAIR VOLUME

Monotherapy	In combination with treatments
+32%**	+41%**

After **3 MONTHS**

HAIR ASPECTS

Monotherapy	In combination with treatments
From +37%** to +42%**	From +42%** to +46%**

1. Hair aspects were assessed using a Numerical Rating Scale from 0 (very slight) to 10 (very high). The reported number indicates the percentage change from baseline.

*Stem-cell therapy, low level light therapy, micro needling and other emerging therapies.

**p<0.001 vs baseline

Presented at the European Academy of Dermatology and Venereology Annual Congress, 30 September – 3 October 2026, Vienna, Austria